Sort
15,273 grants matching “antimicrobial resistance”
Innate, Transcriptomic, and Microbiomic correlates of TB infection
$644,317Michael Haggai Glickman · Weill Medical Coll Of Cornell Univ · U19 · FY2019 · AI
Risk factors for drug resistant pneumococcal bacteremia
$644,259Joshua P Metlay · University Of Pennsylvania · R01 · FY2008 · AI
DNA gyrase and quinolone resistance in tuberculosis
$644,089Karl A Drlica · Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2007 · AI
Task A104: Refining the Model of diabetic murine UTI for testing antimicrobial therapies for E. coli
$643,620Connie Barton · University Of Texas Med Br Galveston · N01 · FY2017 · AI
Combinatorial Approaches to Improved Blood-contacting Polymer Biomaterials
$643,527Christopher A Siedlecki · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2022 · HL
Combinatorial Approaches to Improved Blood-contacting Polymer Biomaterials
$643,522Christopher A Siedlecki · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2023 · HL
Precision targeting of T cell cytotoxicity with PET
$643,445Michael John Evans · University Of California, San Francisco · R01 · FY2025 · CA
The LiaFSR system and antimicrobial peptide resistance in enterococci
$643,198Cesar Augusto Arias · University Of Texas Hlth Sci Ctr Houston · R01 · FY2019 · AI
Determinants, Decision-Making and Outcomes of Antibiotic Use in Advanced Dementia
$643,085Susan L Mitchell · Hebrew Rehabilitation Center For Aged · R01 · FY2010 · AG
Identifying Optimal Antibiotic Regimens to Treat Urinary Tract Infections During Pregnancy
$642,687Anne Mobley Butler · Washington University · R01 · FY2025 · HD
Lactoferrin and lysozyme to promote nutritional, clinical, and enteric recovery: A factorial placebo-controlled randomized trial among children with diarrhea and malnutrition
$642,554Patricia Pavlinac · University Of Washington · R01 · FY2025 · HD
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
$642,515Qi Zhou · Purdue University · R01 · FY2020 · AI
BIOCHEMISTRY OF BACTERIAL CELL MEMBRANES
$642,250University Of California Berkeley · R01 · FY2005 · AI
THIS PROJECT CENTERS ON EXPLORING THE EFFICACY OF NON-ANTIBIOTIC BIOTHERAPEUTICS TO CONTROL ANTIBIOTIC-RESISTANT BACTERIA. ANTIMICROBIAL RESISTANCE IS AN EXPANDING PUBLIC HEALTH CONCERN, WITH METHICILLIN-RESISTANT S. AUREUS (MRSA) AS A PROMINENT EXAMPLE. IT IS PROPOSED THAT DOMESTIC ANIMALS, INCLUDING THOSE OF AGRICULTURAL IMPORTANCE, CAN FUNCTION AS RESERVOIRS AND SHEDDERS OF MRSA, AND MRSA TRANSMISSION BETWEEN ANIMALS AND HUMANS IN BOTH WAYS HAS BEEN REPORTED.OUR LABORATORY STUDIES THE THERAPEUTIC POTENTIAL OF EQUINE MESENCHYMAL STROMAL CELLS (MSCS), A TYPE OF ADULT STEM CELLS ISOLATED FROM THE BLOOD OF HORSES, IN EQUINE WOUND MANAGEMENT. A COMMON COMPLICATION OF EQUINE WOUNDS IS INFECTION WITH BACTERIA, SUCH AS MRSA, AND WE RECENTLY FOUND THAT EQUINE MSCS SECRETE FACTORS THAT CAN INHIBIT THE GROWTH OF MRSA.THIS PROJECT WILL WORK ON FURTHER STUDYING THE POTENTIAL OF EQUINE MSC SECRETED FACTORS TO CONTROL MRSA. THE SPECIFIC SCIENCE OBJECTIVES ARE TO IDENTIFY WHICH SPECIFIC MSC SECRETED FACTORS EXHIBIT THE ANTI-MRSA ACTIVITY AND HOW THEY CAN BE DELIVERED EFFECTIVELY TO THE SKIN. MOREOVER, THE EFFICACY OF MSC SECRETED FACTORS TO CONTROL MRSA WILL BE EXAMINED IN VIVO IN HORSES WITH INFECTED WOUNDS.ONCE WE UNDERSTAND HOW EQUINE MSC EXERT THEIR ANTI-MRSA EFFECTS, WE CAN DEVELOP EVIDENCE-BASED STRATEGIES TO (I) CONTROL MRSA INFECTIONS IN HORSES AND REDUCE THE NEGATIVE IMPACTS OF THESE INFECTIONS IN HORSES, (II) PREVENT TRANSMISSION OF MRSA FROM HORSES TO HUMANS, AND (II) DECREASE THE USE OF ANTIBIOTICS BY USING THESE MSC-DERIVED SECRETED FACTORS AS A NON-ANTIBIOTIC BIOTHERAPEUTIC TO CONTROL ANTIBIOTIC-RESISTANT BACTERIA, NOT ONLY IN VETERINARY MEDICINE BUT POTENTIALLY ALSO IN HUMAN MEDICINE.
$642,000Cornell University · · FY2022 · National Institute of Food and Agriculture
^Identification of novel secondary metabolites produced by symbiotic Proteobacte
$641,924Jon Clardy · University Of Wisconsin-Madison · U19 · FY2014 · AI
Emerging multidrug resistance mechanisms in Campylobacter
$641,884Qijing Zhang · Iowa State University · R01 · FY2020 · AI
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
$641,858David M. Lewinsohn · Oregon Health & Science University · R01 · FY2019 · AI
Anti-infectives that target bacterial ribosomes
$641,696Philip R Cunningham · Wayne State University · U01 · FY2007 · AI
The LiaFSR system and antimicrobial peptide resistance in enterococci
$641,586Cesar Augusto Arias · University Of Texas Hlth Sci Ctr Houston · R01 · FY2020 · AI
Ibis T-6,000 Biosensor System
$641,500Cynthia L Sears · Johns Hopkins University · S10 · FY2010 · RR
An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
$641,127Steven Carl George · University Of California At Davis · R01 · FY2021 · EB
Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections
$641,088Daina Zeng · Agile Sciences, Inc. · R44 · FY2015 · AI
Synthesis and transport of outer membrane components across the Gram-negative cell envelope
$640,850Michael Stephen Trent · University Of Georgia · R01 · FY2025 · AI
Development of human adaptive immunity to Staphylococcus aureus
$640,665Juliane Bubeck Wardenburg · Washington University · R01 · FY2025 · AI
Toward targeting bacterial metabolism: Relevance, mechanism and function of DXP synthase
$640,497Caren L. Freel Meyers · Johns Hopkins University · R56 · FY2020 · AI